NIBRT-based Valitacell wins €2m in funding under Horizon 2020

Valitacell gets cash injection to transform how next-generation medicines are produced.

Early-stage biotech company Valitacell has won €2.02m in funding under the latest EU Horizon 2020 (H2020) round.

The funding, under the H2020 SME instrument Phase 2, will fund the advancement and commercialisation of Valitacell’s ChemStress technology for the next two years.

Comments are closed.